Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet
نویسنده
چکیده
1 Department of Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia, 2 Department of Pathology, University of Melbourne, Parkville, VIC, Australia, 3 Department of Medicine, St Vincent’s Hospital, University of Melbourne, Fitzroy, VIC, Australia, 4 Sir Peter MacCallum Department of Oncology, University of Melbourne, East Melbourne, VIC, Australia, 5 Molecular Oncology Laboratory, Oncogenic Signaling and Growth Control Program, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia, 6 Translational Research Laboratory, Cancer Therapeutics Program, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia
منابع مشابه
The MAPK pathway as an apoptosis enhancer in melanoma
Inhibition of RAF/MEK/ERK signaling is beneficial for many patients with BRAF(V600E)-mutated melanoma. However, primary and secondary resistances restrict long-lasting therapy success. Combination therapies are therefore urgently needed. Here, we evaluate the cellular effect of combining a MEK inhibitor with a genotoxic apoptosis inducer. Strikingly, we observed that an activated MAPK pathway p...
متن کاملParadox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
BRAF and MEK inhibitors are effective in BRAF mutant melanoma, but most patients eventually relapse with acquired resistance, and others present intrinsic resistance to these drugs. Resistance is often mediated by pathway reactivation through receptor tyrosine kinase (RTK)/SRC-family kinase (SFK) signaling or mutant NRAS, which drive paradoxical reactivation of the pathway. We describe pan-RAF ...
متن کاملCancer Therapy: Preclinical MEK-Independent Survival of B-RAF Melanoma Cells Selected for Resistance to Apoptosis Induced by the RAF Inhibitor PLX4720
Purpose: To examine mechanisms that determine long-term responses of B-RAF melanoma cells to B-RAF inhibitors. Experimental Design: B-RAF melanoma cells were exposed to the B-RAF inhibitor PLX4720 for prolonged periods to select for cells resistant to apoptosis induced by the inhibitor. The resultant cells were analyzed for activation of extracellular signal regulated kinase (ERK),MAP/ERK kinas...
متن کاملIt takes two to tango--signalling by dimeric Raf kinases.
Raf kinases function downstream of Ras proteins to activate the MEK-ERK pathway which is deregulated in a large number of human cancers. Raf inhibitors are clinically highly effective for the treatment of cancer and melanoma in particular, but have unexpected side effects that include a paradoxical activation of the ERK pathway. These effects seem to be related to the heterodimerization of Raf-...
متن کاملERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.
The use of targeted therapeutics directed against BRAF(V600)-mutant metastatic melanoma improves progression-free survival in many patients; however, acquired drug resistance remains a major medical challenge. By far, the most common clinical resistance mechanism involves reactivation of the MAPK (RAF/MEK/ERK) pathway by a variety of mechanisms. Thus, targeting ERK itself has emerged as an attr...
متن کامل